Beijing Bohui Innovation Biotechnology Group (300318) Fair Value & Analysis
Healthcare · CN · Market cap 3.7B CNY
Fair value as of: Jul 9, 2026
From 4 valuation models · updated 32 days ago
Fair value updated Jul 9, 2026, revised from ¥7.08 to ¥0.9400 (−86.7%) since Jun 24, 2026. Share price +12.2% over the past month.
Below-average quality, and screening another 81% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥1.40). The favourable scenario is already priced in.
- Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (¥0.4900 to ¥1.40). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥3.73 – ¥14.02 · fair‑value band ¥0.4900 – ¥1.40 · the ¥4.95 price screens above the ¥0.9400 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Beijing Bohui Innovation Biotechnology Group (300318) currently trades at ¥4.95, while our model-based Fair Value estimate is ¥0.9400, implying the stock looks roughly 81.0% overvalued today. The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Beijing Bohui Innovation Biotechnology Group generated revenue of 813M CNY at a net margin of -11.7%. Revenue declined 5.8% year over year. It earns a return on equity of -8.0%. Net debt stands at 720M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥0.4900 (bear case) to ¥1.40 (bull case); at ¥4.95, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -81%, 300318 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 4 models by family
Widest divergence: Multiples (¥1.44) versus Dividend Discount (¥0.5800). Highest evidence: Gordon GGM (70).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; albumin; human prothrombin complex; and vaccine for rabies.
Full company description
Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; albumin; human prothrombin complex; and vaccine for rabies. It also provides molecular platform, such as Automatic Real-time Fluorescent Nucleic Acid Cartridge Analyzer(BHQ-III), and GenPlex BHF-VI Nucleic Acid Chip Analyzer; Trace Element Analyzers; Fluorescence Immunoassay Analyzers, and Quantum Dot Analyzer; and detection kits for respiratory, intestinal, reproductive infections, as well as trace element testing, allergen testing, and others. In addition, the company offers mass spectrometers, plate readers, and standardized ion sources; and flash, process, and preparative purification systems. The company was formerly known as Beijing Bohui Innovation Biotechnology Co., Ltd. and changed its name to Beijing Bohui Innovation Biotechnology Group Co., Ltd. in August 2021. Beijing Bohui Innovation Biotechnology Group Co., Ltd. was founded in 2001 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Beijing Bohui Innovation Biotechnology Group reported revenue of ¥825M in FY2025 versus ¥715M in FY2021, a compound +3.6%/yr. Reported net income was −¥91.9M in FY2025.
300318 screens 81% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Beijing Bohui Innovation Biotechnology Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Beijing Bohui Innovation Biotechnology Group (300318) overvalued or undervalued?
What is the fair value of 300318?
What is the quality score of 300318?
What is the revenue of Beijing Bohui Innovation Biotechnology Group (300318)?
What is the net profit margin of 300318?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Beijing Bohui Innovation Biotechnology Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.